Trial record 11 of 12 for:    allostim

Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01065441
Recruitment Status : Withdrawn (Protocol withdrawn for lack of financial support)
First Posted : February 9, 2010
Last Update Posted : November 30, 2012
Hadassah Medical Organization
Information provided by:
Immunovative Therapies, Ltd.

Brief Summary:
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing using extreme cold) and the adjuvant is intentionally mis-matched immune cells (AlloStim-TM) engineered to produce inflammatory cytokines.

Condition or disease Intervention/treatment Phase
Solid Tumors Stage II, Stage III and Stage IV Breast Cancer Colorectal Cancer Prostate Cancer Melanoma Ovarian Cancer Sarcoma Non-small Cell Lung Cancer Biological: AlloStim Procedure: Cryoablation Phase 1 Phase 2

Detailed Description:
This is a Phase I/II clinical study to investigate the optimal protocol and indication for creating a personalized anti-tumor vaccine within the body of patients with cancer. The aim of the study is to evaluate the safety of administration and anti-tumor effect of a vaccine protocol that has three separate steps. Cancer patients generally present with an immune response to cancer biased to a Th2 response, while a Th1 response is considered necessary for mediating anti-tumor immunity. The first step of the study consists of multiple intradermal priming doses of AlloStimTM. The aim of this step is to create Th1 immunity to the alloantigens in AlloStimTM, thus increasing the number of Th1 cells in circulation. The second step of the protocol involves the cryoablation of a selected tumor lesion followed by an intratumoral AlloStimTM injection. The aim of this step is to generate tumor-specific CTL killer cells in the circulation. The final step is an intravenous infusion of AlloStimTM. The aim of this step is to activate circulating Th1 cells, killer cells, and natural killer cells. The further aim of this step is to create an inflammatory environment that can break-down the ability of the tumor to avoid an anti-tumor immune response. In patients with partial responses and recurrence of disease, additional intravenous "booster" infusions are utilized to reactivate the circulating immune cells.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of an Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancers
Study Start Date : December 2009
Estimated Primary Completion Date : December 2011
Estimated Study Completion Date : July 2012

Intervention Details:
  • Biological: AlloStim
    Patients meeting eligibility criteria will be primed with at least three and up to nine intradermal AlloStim-TM injections at a frequency of every 2-8 days at doses between 1-4 x 10^7 cells
  • Procedure: Cryoablation
    Percutaneous cryoablation of selected tumor lesion under CT or US guidance
  • Biological: AlloStim
    intratumoral injection of AlloStim-TM into cryoablated tumor lesion at a dose of 1-6 x 10^7 cells
  • Biological: AlloStim
    intravenous AlloStim-TM at doses between 1 x 10^7 to 1 x 10^9 cells
  • Biological: AlloStim
    Intraperitoneal AlloStim-TM infusion in patients with peritoneal carcinomatosis and/or ascites
  • Biological: AlloStim
    Patients with malignant pleural effusion may receive intrapleural AlloStim-TM infusion at a dose of 5-10 x 10^7 cells.
  • Biological: AlloStim
    Patients with palpable tumors may receive alcohol ablation and intratumoral AlloStim-TM

Primary Outcome Measures :
  1. The primary endpoint is the evaluation of any drug-related toxicity associated with AlloStimTM administration as well as the reversibility of such toxicity. [ Time Frame: 90 days ]

Secondary Outcome Measures :
  1. The secondary end-point is the evaluation of the anti-tumor effect of AlloStimTM administration. [ Time Frame: 1 year ]
  2. The tertiary end-point is the evaluation of the immunological response to AlloStim-TM administration. [ Time Frame: 90 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years or older
  • Stage II-IV including breast cancer, colorectal cancer, non-small cell lung cancer, ovarian or other gynecological cancer, prostate cancer, pancreatic or other GI cancer, melanoma, head or neck cancer or lymphoma/plasmacytoma.
  • Measurable disease determined upon review of abdominal and/or chest CT scan within 60 days of evaluation for study inclusion with a target tumor lesion for cryoablation or alcohol ablation located in liver, kidney, bone, lung, adrenal, pancreas, lymph node, skin, neck or prostate deemed to be accessible for percutaneous access or carcinomatosis or malignant ascites or malignant pleural effusion.
  • When applicable, acceptable cryoablation procedure technique risk: the target tumor for ablation must have adequate distance from adjacent vasculature and other organs to permit safe application of cryoprobe (generally, more than a 2.5cm clearance of the cryoprobe from any vital structure such as the bowel, inferior vena cava, or aorta). The safety assessment of the cryoprobe placement will be made an attending radiologist based on imaging studies.
  • Life expectancy >90 days
  • No bevacizumab (Avastin®) within 6 weeks of planned cryoablation procedure
  • ECOG status 0-2
  • No concurrent medication known to interfere with platelet function or coagulation (e.g., aspirin, ibuprofen, clopidogrel, or warfarin) unless such medications can be discontinued for an appropriate time period based on the drug half-life and known activity (e.g., aspirin for 7 days) prior to cryoablation procedure
  • No low molecular weight heparin preparations unless can be discontinued 8 hours prior to cryoablation
  • At least 2 weeks since prior cytotoxic chemotherapy
  • Absolute granulocyte count ≥ 1,200/mm3
  • Platelet count ≥ 100,000/mm3
  • PT/INR ≤ 1.5

    o INR correctable to ≤ 1.5 or a PT/PTT correctable to normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be monitored weekly prior to the cryoablation day to assure INR is stable. However, heparin or warfarin must be withheld prior to cryoablation such that the above criteria are met.

  • Hemoglobin ≥ 9 g/dL
  • Creatinine ≤ 1.5 mg/dL
  • Total bilirubin ≤ 1.5 times normal
  • Alkaline phosphatase ≤ 2.5 times normal (≤ 5 times normal if liver involvement)
  • Aspartate aminotransferase (AST) or (SGOT) ≤ 2.5 times ULN
  • Alanine aminotransferase (ALT) or (SGPT) ≤ 2.5 times ULN
  • Not pregnant or lactating
  • Patients with child bearing potential must agree to use adequate contraception
  • No psychiatric or addictive disorders or other condition that, in the opinion of the investigator, would preclude study participation
  • Study specific informed consent

Exclusion Criteria:

  • Taking anticoagulant medication for concomitant medical condition (unless can be safely discontinued for cryoablation procedure)
  • Prior allogeneic bone marrow/stem cell or solid organ transplant
  • Chronic use (> 2 weeks) of greater than physiologic doses of a corticosteroid agent (dose equivalent to > 10 mg/day of prednisone) within 30 days of the first day of study drug treatment

    o Topical and inhaled corticosteroids are permitted

  • Concomitant active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, autoimmune thyroid disease, uveitis)
  • Prior experimental cancer vaccine treatment (e.g., dendritic cell therapy, heat shock vaccine)
  • Immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 3 months of study entry
  • History of blood transfusion reactions
  • Known allergy to bovine products
  • Know allergy to murine products
  • Progressive viral or bacterial infection

    o All infections must be resolved and the patient must remain afebrile for seven days without antibiotics prior to being placed on study

  • Cardiac disease of symptomatic nature or cardiac ejection fraction < 45%
  • Symptomatic pulmonary disease or FEV1, FVC, and DLCO ≤ 50% predicted
  • History of HIV positivity or AIDS o HBV and/or HCV positivity is permitted

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01065441

Hadassah-Hebrew University Medical Center
Jerusalem, Israel, 91120
Sponsors and Collaborators
Immunovative Therapies, Ltd.
Hadassah Medical Organization
Principal Investigator: Tamar Peretz, MD Hadassah Medical Organization
Study Chair: Dr. Michael Har-Noy Immunovative Therapies, Ltd.

Additional Information:
Responsible Party: Dr. Michael Har-Noy, Immunovative Therapies, Ltd. Identifier: NCT01065441     History of Changes
Other Study ID Numbers: ITL-002-HMC
First Posted: February 9, 2010    Key Record Dates
Last Update Posted: November 30, 2012
Last Verified: May 2011

Keywords provided by Immunovative Therapies, Ltd.:
breast cancer
colorectal cancer
prostate cancer
ovarian cancer
GI cancer
Renal Cell Carcinoma

Additional relevant MeSH terms:
Prostatic Neoplasms
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Ovarian Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases